Brought to you by 
Athena licenses Phase III Diastat from Upsher-Smith
15 Sep 2014
Executive Summary
Athena Neurosciences has taken an option to license exclusive US marketing rights to Diastat, a new formulation of diazepam now in Phase III clinical trials at the NIH for the treatment of juvenile epilepsy, from Upsher-Smith Labs.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Athena licenses Phase III Diastat from Upsher-Smith
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice